1
|
El Agouri H, Azizi M, El Attar H, El Khannoussi M, Ibrahimi A, Kabbaj R, Kadiri H, BekarSabein S, EchCharif S, Mounjid C, El Khannoussi B. Assessment of deep learning algorithms to predict histopathological diagnosis of breast cancer: first Moroccan prospective study on a private dataset. BMC Res Notes 2022; 15:66. [PMID: 35183227 PMCID: PMC8857730 DOI: 10.1186/s13104-022-05936-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2021] [Accepted: 01/29/2022] [Indexed: 11/18/2022] Open
Abstract
Objective Breast cancer is a critical public health issue and a leading cause of cancer-related deaths among women worldwide. Its early diagnosis and detection can effectively help in increasing the chances of survival rate. For this reason, the diagnosis and classification of breast cancer using Deep learning algorithms have attracted a lot of attention. Therefore, our study aimed to design a computational approach based on deep convolutional neural networks for an efficient classification of breast cancer histopathological images by using our own created dataset. We collected overall 328 digital slides, from 116 of surgical breast specimens diagnosed with invasive breast carcinoma of non-specific type, and referred to the histopathology department of the National Institute of Oncology in Rabat, Morocco. We used two models of deep neural network architectures in order to accurately classify the images into one of three categories: normal tissue-benign lesions, in situ carcinoma or invasive carcinoma. Results Both Resnet50 and Xception models achieved comparable results, with a small advantage to Xception extracted features. We reported high degrees of overall correct classification accuracy (88%), and sensitivity (95%) for detection of carcinoma cases, which is important for diagnostic pathology workflow in order to assist pathologists for diagnosing breast cancer with precision. The results of the present study showed that the designed classification model has a good generalization performance in predicting diagnosis of breast cancer, in spite of the limited size of the data. To our knowledge, this approach can be highly compared with other common methods in the automated analysis of breast cancer images reported in literature.
Collapse
Affiliation(s)
- H El Agouri
- Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, 10100, Rabat, Morocco.
| | - M Azizi
- Datapathology, 20000, Casablanca, Morocco
| | - H El Attar
- Anatomic Pathology Laboratory Ennassr, 24000, El Jadida, Morocco
| | | | - A Ibrahimi
- Medical Biotechnology Laboratory (MedBiotech), Bioinova Research Center, Rabat Medical & Pharmacy School, Mohammed Vth University in Rabat, 10100, Rabat, Morocco
| | - R Kabbaj
- Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, 10100, Rabat, Morocco
| | - H Kadiri
- Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, 10100, Rabat, Morocco
| | - S BekarSabein
- Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, 10100, Rabat, Morocco
| | - S EchCharif
- Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, 10100, Rabat, Morocco
| | - C Mounjid
- Pathology Department, Oncology National Institute, Faculty of Sciences, Mohammed V University, 10100, Rabat, Morocco
| | - B El Khannoussi
- Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, 10100, Rabat, Morocco
| |
Collapse
|
2
|
Touimi SH, N’chiepo D, Mbarki I, Elkacemi H, Elmajjaoui S, Kebdani T, Benjaafar N, Neftah C, Saoud A, Boulaarab J, Jerguigue H, Omor Y, Latib R, El Agouri H, El Khannoussi B. Apocrine Carcinoma of Breast in a Male Patient: Case Report. Tumori 2020. [DOI: 10.1177/0300891620914132] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Introduction: Apocrine carcinoma of breast is a rare type of malignant tumor, the incidence of which varies between 0.3 - 0.4 % of all female breast cancers.Apocrine carcinoma is exceptional in male patients and very few cases have been described in literature. This tumor shows distinct microscopic and immunohistological features. We report an exceptional observation of apocrine carcinoma of breast in a man. Patient and observation: He’s a 54 years old man who had for 2months a painless nodule at the left axillary..The patient had family history of breast and prostate cancers. Physical examination revealed a left axilary lymphadenopathy movable relative to superficial and deep plans with no evidence mass of breasts. MRI of the breast was performed and revealed a mass that was 38 x 10 mm in size.A biopsy of the lymphadenopathy was performed. It objectified a carcinomatous proliferation. An immunohistochemical study showed that tumor cells express Her 2, but do not express estrogenic and progesterone receptors. A tumorectomy of the left breast was performed and didn’t show any malignant lesion of the breast. The axiler dissection of 13 lymphnodes showed 11 metastatics ones with 3 breaking capsular. The diagnosis of apocrine carcinoma of the breast was made in despite of the result of the tumorectomy. The CT did not indicate metastasis. The patient was administered adjuvant chemotherapy then he received radiation therapy on left susclavicular, axila and breast with a total dose of 42Gy,15 fractions of 2.8 Gy on 21 days with no late effects. 1 year of trastuzumab was administrated. There was no recurrence or metastasis approximately 2 years after radiation therapy. Then the patient presented a susclavicular lymphnode that was comfirmed on the pet-scanner with multiple mediastinal lymphnodes. A biopsy of the susclavicular lymphnode comfirmed the progression of the disease. The patient started chemotherapy in association with pertuzumab and trastuzumab. Discussion: Apocrine carcinoma of the breast is a rare malignant tumor whose incidence varies between 0.3% and 4% of all female’s breast cancer and represents 0.5 % of all invasive breast cancers. This tumor is exceptional in men. Indeed, only a dozen cases have been described in the literature . Most neoplasms are slowly progressive, small in size, and are most frequently seen in the axilla. They can be recurrent and metastasize to the lymph node, lung, and bone. Male patients have been advanced disease at presentation compared to women which may be due to lack of public awareness of breast cancer in male. Histologically, it has glandular structures with apocrine features and decapitation secretions. There is cytoplasmic PAS positivity of the tumor cells. The presence of neoplastic glands high in the dermis and immediate subepidermis favors the primary origin of tumor cells from apocrine sweat glands. Apocrine adenocarcinomas are positive for cytokeratins, carcinoembryogenic antigen (CEA) and epithelial membrane antigen (EMA) . Usually, these tumors do not express the estrogen receptor-alpha, progesterone receptors and bcl-2. Apocrine adenocarcinoma has poor prognosis and the prognostic factors include size, histological type, lymph node involvement, and distant metastasis. The 10-year disease free survival rate in the absence of metastasis to the lymph nodes is 56%. Treatment protocols of apocrine carcinoma are similar to non apocrine carcinoma of breast. However studies involving the use of anti androgens are in progress. The treatment of choice is wide local excision with clear margins, with or without regional lymph node dissection. The role of radiation therapy also remains uncertain in the absence of clinical trials. No clear correlation between treatment modality and recurrence in apocrine carcinoma was apparent, and survival rates of apocrine carcinoma were not different from other breast carcinomas. Conclusion: In conclusion, male apocrine carcinoma is a very rare, unique and morphologically-distinctive, invasive ductal carcinoma.. Although immunohistochemical staining might show differences in males, the prognosis is not different from other breast carcinomas. It has different hormonal profile, androgen receptor positivity makes patient with apocrine carcinoma eligible for targeted therapy.
Collapse
Affiliation(s)
- S. H Touimi
- Department of Radiation Oncology, Institut national d’oncologie de Rabat, Maroc
| | - D N’chiepo
- Department of Radiation Oncology, Institut national d’oncologie de Rabat, Maroc
| | - I Mbarki
- Department of Radiation Oncology, Institut national d’oncologie de Rabat, Maroc
| | - H Elkacemi
- Department of Radiation Oncology, Institut national d’oncologie de Rabat, Maroc
| | - S Elmajjaoui
- Department of Radiation Oncology, Institut national d’oncologie de Rabat, Maroc
| | - T Kebdani
- Department of Radiation Oncology, Institut national d’oncologie de Rabat, Maroc
| | - N Benjaafar
- Department of Radiation Oncology, Institut national d’oncologie de Rabat, Maroc
| | - C Neftah
- Department of Radiology, Institut national d’oncologie de Rabat, Maroc
| | - A Saoud
- Department of Radiology, Institut national d’oncologie de Rabat, Maroc
| | - J Boulaarab
- Department of Radiology, Institut national d’oncologie de Rabat, Maroc
| | - H Jerguigue
- Department of Radiology, Institut national d’oncologie de Rabat, Maroc
| | - Y Omor
- Department of Radiology, Institut national d’oncologie de Rabat, Maroc
| | - R Latib
- Department of Radiology, Institut national d’oncologie de Rabat, Maroc
| | - H El Agouri
- Department of Pathology, Institut national d’oncologie de Rabat, Maroc
| | - B El Khannoussi
- Department of Pathology, Institut national d’oncologie de Rabat, Maroc
| |
Collapse
|